This study is for adults with chronic kidney disease (CKD), which means their kidneys don't work as well as they should. People with or without type 2 diabetes can join. They can already be taking medicines called ACE inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB). The study checks if a new drug, BI 690517, helps when taken with another drug called empagliflozin.

The study has two parts. In the first part, participants take empagliflozin or a placebo (a pill that looks like the real pill but has no medicine) for at least 6 weeks. In the second part, they take either BI 690517 or a placebo pill every day. The study lasts 3 to 4 years, with participants visiting the study site 4 times in the first 6 months, then every 6 months after that.

• Participation can last 3 to 4 years, with regular visits to the study site.
• Participants may receive different treatments, including placebo.
• Doctors will check kidney function and other health factors regularly.